Hematologic Oncology

Latest News

January 28th 2020

The Phase II EZH2 Inhibitor Trial

January 28th 2020

Previously Untreated FLT3-Mutated AML

January 28th 2020

CPX-351 for Secondary AML

January 28th 2020

Sequencing Strategies for Later-Line Therapy

January 28th 2020

Venetoclax-Based Chemotherapy Combinations in AML

Latest Videos

Incidence of TA-TMA

Overview of Transplant-Associated Thrombotic Microangiopathy (TA-TMA)

Richard M. Stone, MD, discusses the promise of menin inhibitors in patients with acute myeloid leukemia.

Dr. Stone on the Promise of Menin Inhibitors in AML

Navneet Majhail, MD, MS, of Cleveland Clinic

Dr. Majhail on the Importance of Utilizing Social Media in Oncology

Dr. Cutler on the Toxicity Profile of Belumosudil in cGVHD

Emerging Therapeutic Options in Polycythemia Vera

Real-World Use of Ruxolitinib in Polycythemia Vera

Corey S. Cutler, MD, MPH, FRCPC, of Dana-Farber Cancer Institute

Dr. Cutler on the Efficacy Results of the ROCKstar Study in cGVHD

Sergio A. Giralt, MD, of Memorial Sloan Kettering Cancer Center

Dr. Giralt on the Potential Utility of Omidubicel in Hematologic Malignancies

Dr. Giralt on Omidubicel Vs Standard Umbilical Cord Blood Transplant in Hematologic Malignancies

CME Content

Video

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Marla D. Lipsyc-Sharf, MD; Ashley Frith, MD

Video

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Video

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Video

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Zev A. Wainberg, MD; Manish A. Shah, MD, FASCO; Syma Iqbal, MD

In-Person Event

19th Annual New York GU Cancers Congress™

March 13-14, 2026

Video

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Jennifer R. Brown, MD, PhD; Alexey V. Danilov, MD, PhD; Matthew S. Davids, MD, MMSc

Video

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Stephen V. Liu, MD; Michelle Afkhami, MD; Ignacio I. Wistuba, MD; Helena Yu, MD

In-Person + Virtual Event

Medical Crossfire® – From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

March 24, 2026

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Video

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Video

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Misty D. Shields, MD, PhD; Rujul Parikh, MD

Video

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Charu Aggarwal, MD, MPH, FASCO; Yifan Tu, MD, PhD

Video

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Charu Aggarwal, MD, MPH, FASCO; Mo Ziari, MD

Video

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Zofia Piotrowska, MD, MHS; Shan Guo, MD

Video

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Misty D. Shields, MD, PhD; Michelle Ojemuyiwa, MD

In-Person + Virtual Event

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

February 19, 2026

Video

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Video

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Video

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Video

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

More News

Managing Venetoclax-Associated Toxicity in AML

January 28th 2020

Treatment Options After Second-Line Relapse

January 28th 2020

Venetoclax-Based Regimens for Unfit Patients with AML

January 28th 2020

Relapsed/Refractory Treatment: The MAGNIFY Regimen

January 28th 2020

Determining Second-Line Therapy in FL

January 28th 2020

Hypomethylating Agents for AML

January 28th 2020

QUAZAR: Oral Azacitidine Maintenance in AML

January 28th 2020

Phase III GALLIUM Results and Maintenance Therapy

January 28th 2020

Immunochemotherapy Decision Factors

January 28th 2020

Decision Making on Consolidation Therapy for AML

January 28th 2020

Assessment of Fitness for AML Induction Chemotherapy

January 28th 2020

When to Initiate Therapy for Follicular Lymphoma

January 28th 2020

The Importance of Risk Assessment

January 28th 2020

AML Induction Strategy and Molecular Testing

January 28th 2020

Differential Diagnosis and Staging of Follicular Lymphoma

January 28th 2020

Dr. Vusirikala on Ongoing Research With Blinatumomab in ALL

ByMadhuri Vusirikala, MD

January 28th 2020

Madhuri Vusirikala, MD, professor of internal medicine in the Division of Hematology/Oncology at the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center, discusses ongoing research with blinatumomab (Blincyto) in acute lymphoblastic leukemia (ALL).

Long-Term Data, Novel Regimens Showcase Progress in ALL

ByJessica Hergert

January 27th 2020

Madhuri Vusirikala, MD, discusses recent changes in the treatment paradigm of acute lymphoblastic leukemia, based on data from the 2019 ASH Annual Meeting.

Dr. Diefenbach on Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in FL

ByCatherine M. Diefenbach, MD

January 27th 2020

Catherine M. Diefenbach, MD, discusses polatuzumab vedotin (Polivy) plus obinutuzumab (Gazyva) and lenalidomide (Revlimid) in patients with follicular lymphoma.

Novel Strategies and Agents Emerge in AML Paradigm

ByKristi Rosa

January 25th 2020

Rebecca L. Olin, MD, MSCE, sheds light on the pivotal progress made in acute myeloid leukemia treatment in recent years.

Dr. Yasenchak on Brentuximb Vedotin Plus Nivolumab in Hodgkin Lymphoma

ByChristopher A. Yasenchak, MD

January 24th 2020

Christopher A. Yasenchak, MD, discusses brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) in patients with Hodgkin lymphoma.

Novel Regimens Generate Excitement in Lymphoma Treatment Paradigms

ByCaroline Seymour

January 23rd 2020

Narendranath Epperla, MD, MS, reflects on recent advances in Hodgkin lymphoma and non-Hodgkin lymphoma.

Dr. Vusirikala on the Role of MRD in ALL

ByMadhuri Vusirikala, MD

January 23rd 2020

Madhuri Vusirikala, MD, discusses the role of minimal residual disease in acute lymphoblastic leukemia.

BiTEs, CAR T-Cell Therapy Enhance ALL Armamentarium, But Questions Remain

ByBrittany Cote

January 23rd 2020

Lloyd Damon, MD, discusses the evolution of the treatment paradigm in acute lymphoblastic leukemia.

Hematologic Oncology

Latest News

Latest Videos

Incidence of TA-TMA

Overview of Transplant-Associated Thrombotic Microangiopathy (TA-TMA)

Dr. Stone on the Promise of Menin Inhibitors in AML

Dr. Majhail on the Importance of Utilizing Social Media in Oncology

Dr. Cutler on the Toxicity Profile of Belumosudil in cGVHD

Emerging Therapeutic Options in Polycythemia Vera

Real-World Use of Ruxolitinib in Polycythemia Vera

Dr. Cutler on the Efficacy Results of the ROCKstar Study in cGVHD

Dr. Giralt on the Potential Utility of Omidubicel in Hematologic Malignancies

Dr. Giralt on Omidubicel Vs Standard Umbilical Cord Blood Transplant in Hematologic Malignancies

CME Content

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

19th Annual New York GU Cancers Congress™

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Medical Crossfire® – From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Proactive Adverse Event Management for HER2+ BTC Treatments

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

More News

The DYNAMO Later-Line Regimen

Managing Venetoclax-Associated Toxicity in AML

Treatment Options After Second-Line Relapse

Venetoclax-Based Regimens for Unfit Patients with AML

Relapsed/Refractory Treatment: The MAGNIFY Regimen

Determining Second-Line Therapy in FL

Hypomethylating Agents for AML

QUAZAR: Oral Azacitidine Maintenance in AML

Phase III GALLIUM Results and Maintenance Therapy

Immunochemotherapy Decision Factors

Decision Making on Consolidation Therapy for AML

Assessment of Fitness for AML Induction Chemotherapy

When to Initiate Therapy for Follicular Lymphoma

The Importance of Risk Assessment

AML Induction Strategy and Molecular Testing

Molecular Testing for AML

Differential Diagnosis and Staging of Follicular Lymphoma

Dr. Vusirikala on Ongoing Research With Blinatumomab in ALL

Long-Term Data, Novel Regimens Showcase Progress in ALL

Dr. Diefenbach on Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in FL

Novel Strategies and Agents Emerge in AML Paradigm

Dr. Yasenchak on Brentuximb Vedotin Plus Nivolumab in Hodgkin Lymphoma

Novel Regimens Generate Excitement in Lymphoma Treatment Paradigms

Dr. Vusirikala on the Role of MRD in ALL

BiTEs, CAR T-Cell Therapy Enhance ALL Armamentarium, But Questions Remain

Trending on OncLive

FDA Grants Fast Track Designation to Pelareorep Plus Bevacizumab/FOLFIRI in Second-Line KRAS-Mutant mCRC

FDA Grants Priority Review to Frontline Dato-DXd for Metastatic TNBC Ineligible for Immunotherapy

On World Cancer Day, Northwell Highlights a Blueprint for Consistent, System-Wide Cancer Care

Revisit Every OncLive On Air Episode From January 2026

Real-World Analysis Supports Rethinking Upfront Dose Intensity of Enfortumab Vedotin in Advanced Urothelial Cancer